We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+7.78%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$7.01B
AUM Growth
+$119M
Cap. Flow
-$210M
Cap. Flow %
-2.99%
Top 10 Hldgs %
36.63%
Holding
168
New
9
Increased
52
Reduced
52
Closed
12

Top Buys

Rank Stock Value
1
EVH icon
Evolent Health
EVH
+$40.7M
2
LLY icon
Eli Lilly
LLY
+$35.4M
3
MRK icon
Merck
MRK
+$34M
4
HUM icon
Humana
HUM
+$29.6M
5
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$29.4M

Top Sells

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$57.6M
2
APLS
Apellis Pharmaceuticals
APLS
+$51M
3
BSX icon
Boston Scientific
BSX
+$40.6M
4
HCA icon
HCA Healthcare
HCA
+$39.8M
5
ISRG icon
Intuitive Surgical
ISRG
+$38.3M

Sector Composition

Rank Sector Weight
1 Healthcare 99.05%
2 Industrials 0.87%
3 Energy 0.03%
4 Communication Services 0.01%
5 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRUS
126
DELISTED
Merus
MRUS
$1.17M 0.02%
44,500
-1,200
-3% -$26.3K
ZTS icon
127
Zoetis
ZTS
$31.6B
$1.12M 0.02%
6,496
+5,123
+373% +$886K
RCKT icon
128
Rocket Pharmaceuticals
RCKT
$348M
$1.1M 0.02%
55,600
+19,000
+52% +$384K
VRDN icon
129
Viridian Therapeutics
VRDN
$2.13B
$1.06M 0.02%
44,400
-1,700
-4% -$43.6K
GDX icon
130
VanEck Gold Miners ETF
GDX
$23B
$994K 0.01%
33,000
– –
XENE icon
131
Xenon Pharmaceuticals
XENE
$6.32B
$920K 0.01%
+23,900
New +$950K
DICE
132
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
$846K 0.01%
+18,200
New +$629K
ABBV icon
133
AbbVie
ABBV
$458B
$832K 0.01%
6,174
-11,002
-64% -$1.61M
FDMT icon
134
4D Molecular Therapeutics
FDMT
$526M
$813K 0.01%
+45,000
New +$828K
VTYX
135
DELISTED
Ventyx Biosciences
VTYX
$804K 0.01%
24,500
-1,000
-4% -$34.5K
SPY icon
136
State Street SPDR S&P 500 ETF Trust
SPY
$778B
$798K 0.01%
1,800
– –
ARWR icon
137
Arrowhead Research
ARWR
$12.1B
$738K 0.01%
20,700
-600
-3% -$20.7K
GOOG icon
138
Alphabet (Google) Class C
GOOG
$3.9T
$726K 0.01%
6,000
– –
BCYC
139
Bicycle Therapeutics
BCYC
$270M
$638K 0.01%
25,000
-28,200
-53% -$655K
SEER icon
140
Seer Inc
SEER
$108M
$581K 0.01%
136,133
– –
GRCL
141
DELISTED
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
$555K 0.01%
+145,646
New +$408K
VKTX icon
142
Viking Therapeutics
VKTX
$4.04B
$535K 0.01%
+33,000
New +$691K
XOP icon
143
State Street SPDR S&P Oil & Gas Exploration & Production ETF
XOP
$3.42B
$502K 0.01%
3,900
– –
DGX icon
144
Quest Diagnostics
DGX
$25.1B
$273K ﹤0.01%
1,942
+1,072
+123% +$148K
MCHI icon
145
iShares MSCI China ETF
MCHI
$6.04B
$183K ﹤0.01%
4,100
– –
GDXJ icon
146
VanEck Junior Gold Miners ETF
GDXJ
$7.06B
$178K ﹤0.01%
5,000
– –
TSM icon
147
TSMC
TSM
$2.09T
$110K ﹤0.01%
1,089
+319
+41% +$29.7K
ABCM
148
DELISTED
Abcam PLC
ABCM
$63K ﹤0.01%
+2,573
New +$44.4K
JMIA
149
Jumia Technologies
JMIA
$726M
$61.6K ﹤0.01%
18,000
– –
THC icon
150
Tenet Healthcare
THC
$20.1B
$54.4K ﹤0.01%
+669
New +$47.6K
3 4 5
6
7

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
AI
Advent International Boston, Massachusetts $4.24B AUM 4.24% 1-Year Est. Return

Bellevue Group's Q2 2023 Portfolio in Review

As of Q2 2023, Bellevue Group held 168 positions worth $7.01B, up 1.7% from $6.89B the previous quarter. Its ten largest holdings account for 37% of the portfolio.

Bellevue Group's Q2 2023 filing shows 9 new, 52 increased, 52 reduced and 12 closed positions. Its largest new stake was POINT Biopharma Global Inc. Common Stock: 1,256,197 shares worth $11.4M. The largest sale was Sarepta Therapeutics, an estimated $57.6M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier, followed by Industrials and Energy.

  • Bellevue Group's largest Q2 2023 buy was POINT Biopharma Global Inc. Common Stock: 1,256,197 shares worth $11.4M.
  • Bellevue Group added most to Evolent Health in Q2 2023, an estimated $40.7M increase.
  • Bellevue Group's biggest Q2 2023 reduction was Sarepta Therapeutics, cutting an estimated $57.6M.
  • Bellevue Group fully exited Pfizer in Q2 2023, selling an estimated $30.2M.
  • Bellevue Group's ten largest holdings make up 37% of its $7.01B portfolio in Q2 2023.
  • Bellevue Group opened 9 new positions and closed 12 in Q2 2023.
  • Bellevue Group's portfolio value rose 1.7% quarter-over-quarter to $7.01B.

Based on Bellevue Group's 13F filing for Q2 2023, filed 14 Aug 2023.